X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs MYLAN (US) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   MYLAN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
MYLAN
Dec-14
GLENMARK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs9304,398-   
Low Rs5173,099-   
Sales per share (Unadj.) Rs322.61,505.6-  
Earnings per share (Unadj.) Rs28.5181.4-  
Cash flow per share (Unadj.) Rs39.2291.9-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.0748.4-  
Shares outstanding (eoy) m282.17378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x2.22.5 90.1%   
Avg P/E ratio x25.420.7 122.9%  
P/CF ratio (eoy) x18.512.8 143.8%  
Price / Book Value ratio x4.05.0 79.0%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2061,418,332 14.4%   
No. of employees `00013.725.0 54.9%   
Total wages/salary Rs m18,7180-   
Avg. sales/employee Rs Th6,636.822,786.4 29.1%   
Avg. wages/employee Rs Th1,364.70-   
Avg. net profit/employee Rs Th586.12,745.0 21.4%   
INCOME DATA
Net Sales Rs m91,031569,659 16.0%  
Other income Rs m914-3,321 -27.5%   
Total revenues Rs m91,945566,338 16.2%   
Gross profit Rs m16,154141,677 11.4%  
Depreciation Rs m3,01941,839 7.2%   
Interest Rs m2,85624,572 11.6%   
Profit before tax Rs m11,19371,945 15.6%   
Minority Interest Rs m0-295 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1553,025 104.3%   
Profit after tax Rs m8,03968,625 11.7%  
Gross profit margin %17.724.9 71.4%  
Effective tax rate %28.24.2 670.2%   
Net profit margin %8.812.0 73.3%  
BALANCE SHEET DATA
Current assets Rs m69,887500,805 14.0%   
Current liabilities Rs m32,879391,530 8.4%   
Net working cap to sales %40.719.2 211.9%  
Current ratio x2.11.3 166.2%  
Inventory Days Days8178 104.3%  
Debtors Days Days93107 87.2%  
Net fixed assets Rs m28,892131,789 21.9%   
Share capital Rs m28220,145 1.4%   
"Free" reserves Rs m51,3530-   
Net worth Rs m51,635283,177 18.2%   
Long term debt Rs m41,418423,038 9.8%   
Total assets Rs m125,9541,140,609 11.0%  
Interest coverage x4.93.9 125.2%   
Debt to equity ratio x0.81.5 53.7%  
Sales to assets ratio x0.70.5 144.7%   
Return on assets %8.68.2 105.9%  
Return on equity %15.624.2 64.2%  
Return on capital %15.113.6 110.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m26,5980-   
CASH FLOW
From Operations Rs m16,48174,882 22.0%  
From Investments Rs m-10,133-59,054 17.2%  
From Financial Activity Rs m-4,685-19,731 23.7%  
Net Cashflow Rs m1,770-3,903 -45.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.79 Rs / USD

Compare GLENMARK PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: DISHMAN PHARMA  ALKEM LABORATORIES  TTK HEALTHCARE  CADILA HEALTHCARE  GSK PHARMA  



Today's Market

Sensex Opens Lower; Asian Paints Falls on Weak Q2 Result(09:30 am)

Asian stocks are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 2.2% while the Hang Seng is down 2.2%.

Related Views On News

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

You Can Buy Select Auto Stocks Now for Big Long-Term Returns(The 5 Minute Wrapup)

Oct 17, 2018

Irrespective of the earnings hiccups, these businesses be setting new profit records.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Stop! Read This Before You Cancel Your SIPs(Profit Hunter)

Oct 11, 2018

Read this before you stop your SIP's in equity mutual funds.

Even If IL&FS Group Brought This Correction, this is Right Time to Buy & Sit Tight!(Chart Of The Day)

Oct 12, 2018

Even if IL&FS is the culprit, it may turn out to be a hero if you buy right and sit tight.

Why Oil Cannot Be Sold to India in Rupees(Vivek Kaul's Diary)

Oct 16, 2018

Oil is bought and sold internationally in terms of dollars. And any change to this, will be attacking the exorbitant privilege of the US dollar.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 23, 2018 12:29 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS